Why no news from joondalup and us?, page-2

There are many of us that still believe, if you read some of the other threads.

It is entirely possible that this company's share price will exceed $2-3 at some point (noting that from here, even a share price of 50c will make many investors quite happy).

And given a number of factors, such as the nature of the model (high margins etc), that the product meets an important need and there is a large addressable market, it has the potential to far exceed those prices.

The upside is significant IMO (but please DYOR).

But will HMD deliver on that significant promise? That's the $10 billion dollar question.

Is the product genuinely compelling enough for those who would need to pay for it?

Can the barriers to its effective operation in clinician settings be reasonably overcome?

Can management execute so that the company can deliver on the product's promise for shareholders?

These are open questions in my mind until they are not.